Traduction de «Diffusion innovations » (Anglais → Français) :

diffusion of innovations

diffusion of innovations

Comité d'évaluation de la diffusion des innovations technologiques

innovation [ industrial innovation | technological innovation ]

Modifiers The following fourth-character subdivisions classify morphological changes and are for use with categories N00-N07. Subdivisions .0-.8 should not normally be used unless these have been specifically identified (e.g. by renal biopsy or autopsy). The three-character categories relate to clinical syndromes. Code Title .0 Minor glomerular abnormality Minimal change lesion .1 Focal and segmental glomerular lesions Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis .2 Diffuse membranous glomerulonephritis .3 Diffuse mesangial proliferative glomerulonephritis .4 Diffuse endocapillary proliferative glomerulonephritis ...[+++] .5 Diffuse mesangiocapillary glomerulonephritis Membranoproliferative glomerulonephritis, types 1 and 3, or NOS .6 Dense deposit disease Membranoproliferative glomerulonephritis, type 2 .7 Diffuse crescentic glomerulonephritis Extracapillary glomerulonephritis .8 Other Proliferative glomerulonephritis NOS .9 Unspecified | Minimal change lesion | Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis | Membranoproliferative glomerulonephritis, types 1 and 3, or NOS | Membranoproliferative glomerulonephritis, type 2 | Extracapillary glomerulonephritis | Proliferative glomerulonephritis NOS

indicator of innovation output | innovation headline indicator | innovation output indicator | single innovation indicator

pulmonary diffusing capacity [ DL | diffusing capacity | diffusion capacity | diffusing capacity of the lung | diffusing capacity of the lungs | lung diffusing capacity ]

European Institute of Innovation and Technology [ EIT [acronym] ]

follicular non-Hodgkin's lymphoma with or without diffuse areas morphology code M969 with behaviour code /3

Diffuse non-Hodgkin's lymphoma

3. To continue and extend activities to encourage support for networking and advisory services with a European dimension, such as the help-desk on innovation financing (LIFT), activities to facilitate interfacing at European level between researchers, industry and investors, the existing network of regions of excellence for the creation of enterprises, new networks of European universities and public research centres to promote knowledge diffusion and best practices in technology transfer, and development of a European electronic dire ...[+++]ctory of innovative start-ups (see Objective 3: Encourage the creation and growth of innovative enterprises, and Objective 4: Improve key interfaces in the innovation system).

5. To continue and reinforce transnational cooperation among regions regarding innovation policies, exchange of good practices and pilot experiments to facilitate transnational technology partnerships as well as diffusion of non-technological aspects of innovation, particularly for SMEs (see Objective 4: Improve key interfaces in the innovation system).

This will also include, where appropriate, activities in support of social innovation, and support to demand side approaches such as pre-standardisation or pre-commercial procurement, procurement of innovative solutions, standardisation and other user-centered measures to help accelerate the deployment and diffusion of innovative products and services into the market.

Nevertheless, only a few national and regional programmes provide funding for transnational research and innovation activities carried out by SMEs, the Union-wide diffusion and uptake of innovative solutions or cross-border innovation support services.